EpiTherapeutics, a Copenhagen, Denmark-based biopharmaceutical company developing innovative anti-cancer drugs in the field of epigenetics, recently received an additional investment from Merck Serono Ventures in an extension of its seed funding round.
Merck Serono Ventures joined an investor group that includes Lundbeckfond Ventures, Novo Seeds, SEED Capital and OSI Pharmaceuticals Inc. This financing has brought the total amount raised by the company to date to DKK 51.5m since its inception in October 2008.
The new capital is being used to expand further drug discovery efforts and accelerate the build-up of a pipeline of small-molecule inhibitors against enzymes regulating the transcriptional activation in cancer.
The identification of these inhibitors is done in close collaboration with Prof. Kristian Helin’s laboratory at the Biotech Research and Innovation Centre, University of Copenhagen.
Prof. Helin, co-founder of EpiTherapeutics, is a scientist, who focuses on the discovery and characterization of novel genes and mechanisms involved in the development of human cancer.
The company is led by CEO Dr. Martin Bonde.